US EditionREBOOT Trial Finds No Benefit of Beta Blockers After Uncomplicated Heart Attacks
The REBOOT Trial found no clinical benefit of beta blockers post-uncomplicated heart attack; women had a 2.7% higher mortality risk with treatment over nearly four years.
- The REBOOT trial involved 8,505 individuals who had experienced a heart attack and maintained good heart function, recruited from 109 hospitals in Spain and Italy, and randomly assigned to either receive beta blockers or not.
- This trial responded to uncertainty about beta blockers' benefit in modern care where reperfusion and new drugs lower heart damage and risks significantly.
- Over a median 3.7-year follow-up, the trial found no significant differences in death, recurrent heart attacks, or heart failure hospitalizations between groups.
- A REBOOT substudy reported that women taking beta blockers experienced a 2.7 percentage point increase in absolute mortality risk compared to women not treated with these medications, whereas no similar elevated risk was observed in men.
- The trial is expected to influence clinical guidelines worldwide by enhancing treatment approaches, minimizing adverse effects, and boosting patient well-being, although some experts recommend that patients who tolerate beta blockers continue their use.
27 Articles
27 Articles
REBOOT trial finds no benefit of beta blockers after uncomplicated heart attacks
Beta blockers-drugs commonly prescribed for a range of cardiac conditions, including heart attacks-provide no clinical benefit for patients who have had an uncomplicated myocardial infarction with preserved heart function.
El Huffington Post
According to the study, drugs that have been prescribed for forty years after a myocardial infarction not only do not provide any benefit to patients with uncomplicated heart attacks but also raise the risk of death or reinfarction in women.
Beta blockers may offer no benefit for heart attack patients, and women can have worse outcomes
Beta blockers—drugs commonly prescribed for a range of cardiac conditions, including heart attacks—provide no clinical benefit for patients who have had an uncomplicated myocardial infarction with preserved heart function. Beta blockers have been the standard treatment for these patients for 40 years.
A CNIC-led trial shows that treatment with beta-blockers is not necessary in patients who retain contractile heart function. In the case of women with this profile, these medications can be counterproductive.
A clinical macro-assay, in which more than a hundred Spanish and Italian hospitals have participated, with 8,500 patients and 500 researchers, has confirmed something that until now was only a suspicion among some cardiologists: beta-blockers, a medicine prescribed for more than four decades to the survivors of heart attack, do not bring benefits to most patients. And, in some cases, they can even be harmful and in particular to women. The resea…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
